CAY10568, also known as Santinamide, is primarily utilized in research settings for its role as a selective inhibitor of histone deacetylase 6 (HDAC6). This compound is widely studied for its potential therapeutic applications in cancer treatment, as HDAC6 inhibition can disrupt the function of oncogenic proteins and induce cancer cell death. Additionally, it is explored in neurodegenerative diseases due to its ability to modulate protein aggregation and degradation pathways, which are critical in conditions like Alzheimer's and Parkinson's disease. Researchers also investigate its anti-inflammatory properties, making it a candidate for treating inflammatory and autoimmune disorders. Its specificity for HDAC6 makes it a valuable tool for understanding the biological functions of this enzyme and its implications in various diseases.